CClinicalTrials.gg
CompletedNCT00614016Updated Aug 5, 2008

A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers

A Phase 1 interventional study of Sodium ST20 in Healthy, sponsored by HemaQuest Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-08-05.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 1 and Interventional

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A safety and pharmacokinetic study of a single dose of ST20 in healthy volunteers

Read the detailed description

A Phase 1 study in healthy volunteers to assess the safety and pharmacokinetics of ST20 after oral administration of a single-dose. In addition, a comparison of the pharmacokinetics and exposure of a single dose of ST20 under fasting and non-fasting conditions will be assessed.

02

Conditions studied

  • Healthy

Keywords

  • healthy volunteers
03

In context

Lead sponsor

HemaQuest Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Be a healthy male or female
  • Be between the ages of 18 and 45 years old, inclusive
  • Be able and willing to give informed consent
  • Be able to comply with all study procedures
  • If female, not be pregnant, including negative serum pregnancy test
  • If female, must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and throughout the study: hormonal (i.e., oral, transdermal, implant or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD); vasectomized partner (six months minimum); or abstinence. Male subjects must also agree to use one or more of the above forms of birth control for either themselves or their partner, as appropriate throughout the course of the study
  • Must not be receiving prescription medication within the 2 weeks before administration of the test dose, except for multivitamins or contraception
  • Have white blood cell count, hemoglobin, hematocrit and platelet count within normal range for the testing facility
  • Must have serum chemistry values and urinalysis values within the limits of normal for the testing facility
  • Must have coagulation parameters within the limits of normal for the testing facility
  • Must have a negative urine test for substances of abuse including marijuana, cocaine, cocaine derivatives, opiates and methadone

Exclusion criteria

Exclusion Criteria:

  • Have clinically significant vital signs
  • Have any clinically significant laboratory value (CBC, serum chemistry, or urinalysis)
  • Have made a blood donation of 500mL within the 2 months before administration of study medication
  • Have received a blood transfusion within the 3 months before administration of study medication
  • Have an acute febrile illness or upper respiratory tract illness within 72 hours prior to administration of study medication
  • Have received another investigational agent within the 4 weeks before administration of test drug
  • Have received any other investigational agent during this study
  • Have any acute or chronic disease (e.g., history of hepatitis or HIV-1)
  • Have cardiac disease including congestive heart failure or arrhythmia
  • Have a history of central nervous system disease, such as seizures
  • Be breast feeding a child
  • Have been a smoker in the past 12 months
  • Have Body Mass Index (BMI) > 33 kg/m2
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    single

    8 subjects total (6 active and 2 placebo)

    Drug: Sodium ST20

Interventions

  • DrugSodium ST20

    single administration of oral dosage form

06

What researchers measure

Primary outcomes

  1. safety, maximum tolerated dose

    Time frame: specified timepoints in the protocol

Secondary outcomes

  1. pharmacokinetics

    Time frame: specified timepoints in the protocol

07

Study locations

1 site
  • Charles River Clinical Services Northwest, Inc.
    Tacoma, Washington 98418, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00614016
Lead sponsor
HemaQuest Pharmaceuticals Inc.
First posted
Feb 13, 2008
Start date
Jan 2008
Primary completion
Apr 2008
Completion
Jun 2008
Last update
Aug 5, 2008

Study contacts

Robin Downey, MD
principal investigator · Charles River Clinical Services Northwest, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion